All News

2020

May

Media Release / May 29, 2020

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Read More
Media Release / May 29, 2020

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Illustration of the coronavirus created at the Centers for Disease Control and Prevention (CDC)
Featured News / May 28, 2020

Coronavirus (COVID-19) news feed

Read More
Media Release / May 28, 2020

Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)

Read More
Featured News / May 27, 2020

Novartis update following WHO Solidarity trial announcement

Read More
Woman at a work bench
Featured News / May 27, 2020

Novartis at ASCO

Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO)

Read More
Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)

Read More
Media Release / May 26, 2020

Novartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees

Read More
Media Release / May 19, 2020

AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More